

LETTER TO THE EDITOR

**Is there a relationship between disease duration and P-wave dispersion in patients with psoriasis?**

BILGE BULBUL SEN<sup>1</sup>, EMINE NUR RIFAIIOGLU<sup>1</sup>, OZLEM EKIZ<sup>1</sup>, EYUP BUYUKKAYA<sup>2</sup> & NIHAT SEN<sup>2</sup>

<sup>1</sup>Department of Dermatology, Mustafa Kemal University School of Medicine, Hatay, Turkey, and <sup>2</sup>Department of Cardiology, Mustafa Kemal University School of Medicine, Hatay, Turkey

Dear Editor

We have read with great enthusiasm the recently published article entitled ‘Electrocardiographic P-wave characteristics in patients with psoriasis vulgaris’ by Bacaksız and co-workers (1). They concluded that Pmax and P-wave dispersion (PWD) were significantly higher in psoriasis patients than in controls ( $108.8 \pm 21.3$  ms versus  $93.3 \pm 13.0$  ms,  $P < 0.01$ ;  $67.4 \pm 22.9$  ms versus  $45.0 \pm 19.6$  ms,  $P < 0.01$ , respectively). Furthermore, Pmin was significantly lower in the psoriasis group ( $41.3 \pm 12.3$  ms versus  $48.3 \pm 14.3$  ms,  $P = 0.04$ ) (1). Recently, Ahlehoff et al. showed that psoriasis is associated with an increased risk of atrial fibrillation (AF) (2). Prolongation of PWD has been demonstrated to be an independent risk factor for the development of AF. Therefore, the subject is important in daily practice, and the study deserves further attention, keeping in mind its successful design and results.

Bacaksız et al. showed (1) that the Psoriasis Area and Severity Index (PASI) score was correlated with Pmax and PWD ( $P = 0.002$  and  $P = 0.005$ , respectively). In addition, there was a significant positive correlation between hsCRP and PWD ( $r = 0.229$ ,  $P = 0.001$ ). It was speculated that although the exact mechanism still remains unclear, chronic inflammation may be responsible for the correlation between PASI score and PWD in these patients. Psoriasis is a chronic inflammatory disease, and the inflammation continues for the duration of the disease. Hence, a significant positive correlation between duration of

the disease and PWD would be expected. We believe that an evaluation of the relationship between duration of the disease and PWD will help us to understand the increased frequency of AF in patients with psoriasis.

In addition, patients with coronary artery disease (CAD) were excluded in the study of Bacaksız et al (1). Epidemiological studies in patients with severe psoriasis have revealed that there is an increased risk of cardiovascular mortality (3,4), and the cardiovascular disease risk has been found to be particularly high in young patients with a severe form of the disease (5,6). It has been postulated that premature occurrence of atherosclerosis is related to why psoriasis patients have an increased risk for developing cardiovascular disease. As we know, there is an important relationship between psoriasis and subclinical coronary atherosclerosis, independent of conventional cardiovascular disease risk factors (7–9). Bacaksız et al. (1) did not specify how CAD was excluded, but there might be some subclinical atherosclerosis in their patients. In a previous study, PWD was found to be more significant in patients with stable CAD than in patients with normal coronary angiograms and to be associated with severity of the disease as well (10). Therefore, it would have been helpful if Bacaksız and co-workers had clearly identified these factors.

**Declaration of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

## References

1. Bacaksiz A, Erdogan E, Tasal A, Vatankulu MA, Kul S, Sevgili E, et al. Electrocardiographic P-wave characteristics in patients with psoriasis vulgaris. *Ups J Med Sci.* 2013;118:35–41.
2. Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. *Eur Heart J.* 2012;33:2054–64.
3. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. *Eur Heart J.* 2010;31:1000–6.
4. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. *Arch Dermatol.* 2009;145:700–3.
5. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case–control analysis. *Br J Dermatol.* 2009;160:1048–56.
6. Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, et al. [Integrated approach to comorbidity in patients with psoriasis]. *Actas Dermosifiliogr.* 2012;103:1–64.
7. Yiu KH, Yeung CK, Zhao CT, Chan JC, Siu CW, Tam S, et al. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. *J Intern Med.* 2013;273:273–82.
8. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA.* 2006;296:1735–41.
9. Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. *Dermatology.* 2009;218:110–13.
10. Yilmaz R, Demirbag R. P-wave dispersion in patients with stable coronary artery disease and its relationship with severity of the disease. *J Electrocardiol.* 2005;38:279–84.